AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04190433
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04280536
Drug: Cohort A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
Trial: NCT04280536
Drug: Cohort B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
Trial: NCT03882775
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin with or without gpi during emergency PCI.
Trial: NCT01196039
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT01762462
Drug: SAR302503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT01689909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
Trial: NCT03350984
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.
Trial: NCT00771004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
Trial: NCT02183155
Drug: Meloxicam - low
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183155
Drug: Meloxicam - medium
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183155
Drug: Meloxicam - high
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183155
Drug: Extended-release indomethacin
RxNorm normalized name: indomethacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03628924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
Trial: NCT01572506
Drug: Biotin RBC survival
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04198818
Drug: HH2710
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
Trial: NCT04066244
Drug: BLZ945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug capsules taken orally or via enteral infusion
Trial: NCT00766441
Drug: sulphonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphonylurea, variable, od or bd, during ramadan
Trial: NCT03023046
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03023046
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01600742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.
Trial: NCT04682873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed.
Trial: NCT01879527
Drug: Amiloride hydrochlorothiazide
RxNorm normalized name: amiloride / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
Trial: NCT02607449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without any active pharmaceutical ingredients
Trial: NCT00664027
Drug: RTA 402 (Bardoxolone Methyl)
RxNorm normalized name: METHYLAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
Trial: NCT03818919
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03818919
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03818919
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT00582283
Drug: I124-NM404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-124-NM404
Trial: NCT00240305
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04005339
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
Trial: NCT04005339
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 2,400 mg/m IV over 46 hours.
Trial: NCT02477267
Drug: SL spray
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02245360
Drug: Phleum pratense grass pollen allergen extract
RxNorm normalized name: Phleum pratense allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
Trial: NCT02442349
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tablet 80 mg
Trial: NCT01539083
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 300 mg/m\^2 orally.
Trial: NCT01539083
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 50 mg orally.
Trial: NCT04243109
Drug: Pomalidomide + Cyclophosphamide + Dexamethasone
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained.
Trial: NCT01788176
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
Trial: NCT01788176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one single intravenous infusion of 100ml of saline.
Trial: NCT00882310
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
Trial: NCT04542161
Drug: NAC 900mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self administer NAC 900mg/day caplets for a four week period
Trial: NCT04542161
Drug: NAC 3600mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self administer NAC 3600mg/day caplets for a four week period
Trial: NCT04542161
Drug: NAC 0mg/day (Placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self administer NAC 0mg/day (placebo) caplets for a four week period
Trial: NCT00472173
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apexification treatment of the tooth with Calcium hydroxide
Trial: NCT04252859
Drug: [18F]Fluoroestradiol (FES) PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
Trial: NCT00601705
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
Trial: NCT01127945
Drug: statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy
Trial: NCT02673606
Drug: Estradiol 2Mg Tablet
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
Trial: NCT02673606
Drug: Estradiol 4Mg Tablet
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
Trial: NCT04171531
Drug: Botox® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.
Trial: NCT02651714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01646294
Drug: YM178 modified release (OCAS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01646294
Drug: YM178 immediate release (IR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01515540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01597388
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
Trial: NCT04494815
Drug: SR419 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive 2 doses of SR419 placebo oral suspension.
Trial: NCT04494815
Drug: active control placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive 2 doses of active control placebo capsule.
Trial: NCT04251156
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
Trial: NCT02285283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06293261
Drug: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental only, not included active and placebo comparator
Trial: NCT02477423
Drug: Gentamicins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
Trial: NCT02477423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be given as placebo for those in the placebo comparator group.
Trial: NCT03956355
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream applied once daily
Trial: NCT00708201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02179671
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 once daily followed by MEDI4736
Trial: NCT00696475
Drug: Diazoxide choline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00696475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03463369
Drug: Nucleos(t)ide Analogs (NA)
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NA as a standard of care treatment.
Trial: NCT02964403
Drug: Cox-2
RxNorm normalized name: COX-2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02964403
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02546765
Drug: IV acetaminophen & IV propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of IV tylenol and IV propofol for pain and sedation (respectively)
Trial: NCT02546765
Drug: IV acetaminophen & IV dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
Trial: NCT01395251
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone 20 mg once a day per os for 3 subsequent days
Trial: NCT04218123
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral intake
Trial: NCT00396747
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00396747
Drug: Methotrexate + Methylprednisolone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02064920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for donepezil hydrochloride capsule
Trial: NCT00579436
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 inert capsules daily by mouth for 12 weeks.
Trial: NCT01299701
Drug: ASA404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
Trial: NCT04679545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inactive compound.
Trial: NCT01147016
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As prescribed by physician, standard of care.
Trial: NCT01147016
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed by physician, standard of care.
Trial: NCT03791918
Drug: TACE Drug Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
Trial: NCT02024646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via subcutaneous injection until week 24.
Trial: NCT01271933
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet; given once daily
Trial: NCT02059187
Drug: MK-1293
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Trial: NCT02059187
Drug: Lantus™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lantus™ (insulin glargine \[rDNA origin\]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Trial: NCT01935531
Drug: 3% diclofenac in 2.5% hyaluronic acid gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01090713
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-70mg; oral
Trial: NCT00190944
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00848003
Drug: Bifidobacterium animalis subsp. lactis strain BB-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
Trial: NCT00848003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry flavored yogurt
Trial: NCT01489371
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04309474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT00063193
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00063193
Drug: creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02717754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir matched placebo will be administered intravenous for 5 days.
Trial: NCT01200238
Drug: STA-9090
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00679055
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
Trial: NCT02920424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo.
Trial: NCT03101579
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
Trial: NCT00528879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
Trial: NCT00644605
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
Trial: NCT02605083
Drug: eFT508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be given orally once or twice daily. Each treatment cycle = 21 days.
Trial: NCT01873703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01081483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description for more information